| pNX | Regional lymph nodes cannot be assessed (e.g., previously removed or not removed for pathologic study). |
| pN0 | No regional lymph node metastasis identified histologically. |
| Note: ITCs are defined as small clusters of cells ≤0.2 mm, or single tumor cells, or a cluster of <200 cells in a single histologic cross-section. ITCs may be detected by routine histology or by IHC methods. Nodes containing only ITCs are excluded from the total positive node count for purposes of N classification but should be included in the total number of nodes evaluated. |
| pN0(i–) | No regional lymph node metastases histologically, negative IHC. |
| pN0(i+) | Malignant cells in regional lymph node(s) ≤0.2 mm (detected by H&E or IHC including ITC). |
| pN0(mol–) | No regional lymph node metastases histologically, negative molecular findings (RT-PCR). |
| pN0(mol+) | Positive molecular findings (RT-PCR), but no regional lymph node metastases detected by histology or IHC. |
| pN1 | Micrometastases. |
| OR |
| Metastases in 1–3 axillary lymph nodes. |
| AND/OR |
| Metastases in internal mammary nodes with metastases detected by sentinel lymph node biopsy but not clinically detected.c |
| pN1mi | Micrometastases (>0.2 mm and/or >200 cells but none >2.0 mm). |
| pN1a | Metastases in 1–3 axillary lymph nodes, at least one metastasis >2.0 mm. |
| pN1b | Metastases in internal mammary nodes with micrometastases or macrometastases detected by sentinel lymph node biopsy but not clinically detected.c |
| pN1c | Metastases in 1–3 axillary lymph nodes and in internal mammary lymph nodes with micrometastases or macrometastases detected by sentinel lymph node biopsy but not clinically detected. |
| pN2 | Metastases in 4–9 axillary lymph nodes. |
| OR |
| Metastases in clinically detectedd internal mammary lymph nodes in the absence of axillary lymph node metastases. |
| pN2a | Metastases in 4–9 axillary lymph nodes (at least 1 tumor deposit >2 mm). |
| pN2b | Metastases in clinically detectedd internal mammary lymph nodes in the absence of axillary lymph node metastases. |
| pN3 | Metastases in ≥10 axillary lymph nodes. |
| OR |
| Metastases in infraclavicular (level III axillary) lymph nodes. |
| OR |
| Metastases in clinically detectedc ipsilateral internal mammary lymph nodes in the presence of one or more positive level I, II axillary lymph nodes. |
| OR |
| Metastases in >3 axillary lymph nodes and in internal mammary lymph nodes with micrometastases or macrometastases detected by sentinel lymph node biopsy but not clinically detected.c |
| OR |
| Metastases in ipsilateral supraclavicular lymph nodes. |
| pN3a | Metastases in ≥10 axillary lymph nodes (at least 1 tumor deposit >2.0 mm). |
| OR |
| Metastases to the infraclavicular (level III axillary lymph) nodes. |
| pN3b | Metastases in clinically detectedd ipsilateral internal mammary lymph nodes in the presence of one or more positive axillary lymph nodes; |
| OR |
| Metastases in >3 axillary lymph nodes and in internal mammary lymph nodes with micrometastases or macrometastases detected by sentinel lymph node biopsy but not clinically detected.c |
| pN3c | Metastases in ipsilateral supraclavicular lymph nodes. |
| Posttreatment ypN |
| –Posttreatment yp "N" should be evaluated as for clinical (pretreatment) "N" methods above. The modifier "SN" is used only if a sentinel node evaluation was performed after treatment. If no subscript is attached, it is assumed that the axillary nodal evaluation was by AND. |
| –The X classification will be used (ypNX) if no yp posttreatment SN or AND was performed. |
| –N categories are the same as those used for pN. |